This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.
Abigail Beaney July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The new legislation will reduce the time it takes for patients to receive these therapies from months to days. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
We talked about the many closed-door conversations happening during vendor evaluations, RFP processes, or internal strategy meetings and identified some core questions access experts should be asking teams—internal or external. Look for a vendor with clear escalation processes when AI reaches its limits.
It will also negatively affect access to coverage and care for people that obtain their health coverage through the ACA Marketplace and Medicare. The proposed reconciliation bill heightens the risk that millions of Americans will lose access to care and coverage by shifting even more Medicaid costs to the states.
August 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook TfR1 CapX is an intravenously administered AAV capsid that targets the human transferrin receptor. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Credit: Nekrasov Eugene/Shutterstock.com.
By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe. A first-in-human Phase I study involving patients with relapsed or refractory B-cell lymphoma is expected to commence using AVC-203 in the second half of 2025.
Transitions of care, or the movement of patients between health care settings or providers, impose a significant cost on the health care system due to frequent adverse events and hospital readmissions. 2 Although various programs aim to mitigate these risks, pharmacist-driven initiatives have proven particularly effective.
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
These third-party administrators act as intermediaries between drug manufacturers, pharmacies, and insurance companies. PBMs negotiate prices, establish formularies, and process claims, while also creating preferred networks of pharmacies. Additionally, the role of pharmacy benefit managers (PBMs) cannot be overlooked.
First-generation oral cephalosporins (ie, cephalexin and cefadroxil) have excellent coverage of methicillin-susceptible S aureus and Streptococcus spp, making them ideal agents for treatment. Typically, empiric coverage for UTIs includes Escherichia coli and Klebsiella pneumoniae.
August 12, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The companies will work together using the NanoSpark tech to develop novel products to meet demands within the fast-growing cell and gene therapy markets. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Transition to NDC-12 codes will significantly impact the pharmaceutical supply chain, affecting manufacturing, distribution, and reimbursement processes. Increased regulatory engagement highlights the importance of updating SOPs to ensure compliance and effective documentation of processes. 27, 2025 Dispensers with 26+ staff until Nov.
Tafamidis, a selective transthyretin stabilizer, significantly reduces mortality and hospitalizations in ATTR-CM patients. SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis.
Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process. Beyond improving medication safety, pharmacogenetics enhances clinical efficiency by reducing the reliance on trial-and-error prescribing.
The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers. May 12, 2025.
These forward-thinking leaders bring fresh ideas that are making a powerful impact across hospitals, health systems and healthcare companies. Amick was appointed CEO of Visante in July 2025, bringing over 30 years of leadership experience in healthcare technology and services to the organization.
Intelligent medication management systems using RWD help hospitals forecast demand, respond to crises, and minimize medication expiration and loss, ultimately improving patient care and operational efficiency. million drugs are given or prescribed annually in hospital emergency departments alone.
June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The alliance between the two entities will increase the production of new cancer therapies such as CAR T-cell treatment. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
June 16, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Ethris’ platform technologies have shown favourable results in Phase I trials for ETH47. These platforms are designed for safe drug production while allowing scaleable manufacturing processes. Credit: Cryptographer/Shutterstock.
Rilonacept therapy management involves carefully evaluating patient disease stability, flare risks, and potential for discontinuation through a shared decision-making process. In an interview with Pharmacy Times ®, Allan L.
The Drug Channels Institute, an HMP Global Company, which published an annual report, “The 2024-2025 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors,” estimated that 2024 drug-distribution revenue of the Big Three was $776 billion in 2024.
July 7, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The collaboration will advance paediatric healthcare by focusing on cell and gene therapies. Together, they will establish the Abu Dhabi – Children’s National Hospital Cell and Gene Therapy Clinical Excellence Programme.
Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. Topic sponsors are not involved in the creation of editorial content.
2 The following cases underscore the importance of diligence and vigilance in our procurement processes. The investigation revealed that the hospital had acquired the product from an unauthorized gray market distributor in Florida, via a supply chain linked to illicit traders in Dubai and Delhi. April 14, 2025.
Someone ended up donating a car, and they used the money to buy tires and insurance. When patients get discharged from the hospital at night, they call her at home, and she comes in to fill their prescriptions. It seems to streamline the process,” Loy-Helm said. One service at Russell Springs Pharmacy is pill packing.
June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The treatments can be accessed through facilities such as Royal Prince Alfred Hospital, Westmead Hospital and the Sydney Children’s Hospitals Network. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Robert Barrie June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook CAR-Ts, the first of which were initially approved in June 2025, have demonstrated a wealth of efficacy in haematological oncology indications. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Robert Barrie July 1, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Shares in NYSE-listed AbbVie closed 1.7% Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. higher following the deal. Valeriya Zankovych via Shutterstock.
Insurancecoverage for GLP-1 medications can be a barrier, as they are often not covered for non-diabetic uses, necessitating pharmacist guidance. Clinical studies show significant weight loss and symptom improvement in PCOS patients treated with semaglutide, with minimal adverse effects reported.
July 9, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The JUST-AAV platform features a range of vector types optimised for several target tissues, enhancing the potential of AAV-based gene therapy. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock. Give your business an edge with our leading industry insights.
Abigail Beaney July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Sarepta will pause shipments of the therapy to the US while it discusses the therapy with the FDA. Sarepta confirmed it will work with the FDA to respond to requests for information while advancing the Elevidys safety labelling supplement process.
Robert Barrie and Abigail Beaney July 29, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The FDA determined the third patient death after treatment with Elevidys was not linked to the gene therapy. GlobalData forecasts full-year 2025 revenue for Elevidys of $1.41bn. Image credit: T.
July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The rare and fatal lysosomal storage disorder primarily impacts the brain. The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. Credit: Kateryna Kon/Shutterstock.
It’s a directive that hospitals and health systems of every size know well — whether sprawling academic medical centers, multistate nonprofit systems or rural, independent 25-bed hospitals. To meet this challenge, Infirmary Health redesigned its clinical documentation integrity process without adding staff.
1 There are specific diseases—including hemophilia and sickle cell disease (SCD)—that are more widespread in groups enrolled in Medicaid than commercially insured individuals, due to the program’s concentration on children, disabled adults, and those families financially impacted by treatment costs. of average manufacturer price.
Abigail Beaney July 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The refusal comes based on the Phase III EMBARK trial, which failed to meet its primary endpoint. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Image credit: Dilok Klaisataporn / Shutterstock.com.
Robert Barrie June 16, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Elevidys is the only gene therapy approved in US for DMD. The first death due to ALF, announced in March 2025, prompted the suspension of multiple clinical trials evaluating the gene therapy in different patient populations with DMD.
Robert Barrie June 17, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Eli Lilly has already secured several billion-dollar deals in 2025. Eli Lilly has already spent big in 2025. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Credit: JHVEPhoto via Shutterstock.
Robert Barrie July 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Prasad, an oncologist who was a fierce critic of the Covid-19 vaccine response in the US, was appointed only three months ago. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
July 17, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The announcement included updates on Elevidys’ label changes for Duchenne muscular dystrophy treatment. The company anticipates $100m in cost savings by the end of 2025 after accounting for severance costs between $32 and $37m.
Robert Barrie June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. The OTP is part of the Center for Biologics Evaluation and Research (CBER) and responsible for reviewing applications cell and gene therapy products.
Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content